Completing data — refresh the page later to see the latest
112901-68-5NCCCNCCSP(=O)(O)O.O.O.OTXQPXJKRNHJWAX-UHFFFAOYSA-NSee also: Amifostine (broader).
112901-68-5DTXSID40150210Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 40 reports by companies from 2 notifications to the ECHA C&L Inventory.
DescriptionAmifostine is a broad-spectrum cytoprotective agent, once used as a military anti-radiation agent, and now used as a protective drug for radiotherapy and chemotherapy. It has significantly effective in reducing the side effects of anticancer drugs such as cyclophosphamide, ciplatin, doxorubicin, and anti-HIV drugs such as 3-azido-3-deoxythymidine, without affecting the efficacy of anticancer or anti-HIV drugs curative effect. At present, the commercially available amifostine products include freeze-dried powder injection(ETHYOL )produced by American Life Sciences Co., Ltd. It is only available as a lyophilized powder for injection, but is thermally unstable.
UsesProtectant (topical); radioprotector.
UsesAmifostine may provide renal protection during PRRT using somatostatin analogs by mitigating radiation damage and reducing the absorbed kidney radiation dose. Amifostine remediates the degenerative effects of radiation on the mineralization capacity of the murine mandible.